ReviewAnimal models and experimental medicine2018
To develop a novel animal model of myocardial infarction: A research imperative.
Review in Animal models and experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease.Frontiers in cardiovascular medicine · 2020Pooled it
- mRNA medicine for cardiovascular disease.Nature cardiovascular research · 2026Review
- In vivo growing leporine model of pulmonary artery banding induces inflammation and vascular remodeling via pathways conserved across species.JTCVS open · 2026Article
- Effect of metformin in a novel experimental model of peripheral artery disease.Clinical science (London, England : 1979) · 2025Article
- Genetic Animal Models of Cardiovascular Pathologies.Biomedicines · 2025Review
- Metabolomics of repetitive myocardial stunning in chronic multivessel coronary artery stenosis: Effect of non-selective and selective β1-receptor blockers.The Journal of physiology · 2024Article
- Research progress on the natural products in the intervention of myocardial infarction.Frontiers in pharmacology · 2024Review
- Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient miceActa pharmaceutica Sinica. B · 2023Article
- Morbidity and mortality in elderly dogs - a model for human aging.BMC veterinary research · 2022Article
- Fluoroscopy Guided Minimally Invasive Swine Model of Myocardial Infarction by Left Coronary Artery Occlusion for Regenerative Cardiology.Cardiology and cardiovascular medicine · 2022Article
- The Prominin-1-Derived Peptide Improves Cardiac Function Following Ischemia.International journal of molecular sciences · 2021Article
- Current Status and Limitations of Myocardial Infarction Large Animal Models in Cardiovascular Translational Research.Frontiers in bioengineering and biotechnology · 2021Review
- Development and Long-Term Follow-Up of an Experimental Model of Myocardial Infarction in Rabbits.Animals : an open access journal from MDPI · 2020Article
- To develop a novel animal model of myocardial infarction: A research imperative.Animal models and experimental medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although great progress has been made in therapeutic interventions for coronary artery disease (CAD), it is still the deadliest disease in the world. Currently animals that are similar to human beings in their cardiovascular pathophysiology are being used to explore the pathogenesis and therapy of CAD. There have been a series of developments in creating CAD animal models using mice, rats, rabbits, dogs, and pigs, but unfortunately there is still no acceptable model for human CAD. The ideal CAD animal model should satisfy several conditions as follows. First of all, it should have a pathophysiological process for CAD that is similar to humans. Second, it should be useable for assessing drug efficacy. The last and most important condition is that the model can be used to duplicate clinical therapeutic skills. The limitations of current methods for making animal models have meant that these models not only do not duplicate the actual pathogenesis, but also cannot be used to simulate clinical therapy, and do not support scientific evaluation of drug efficacy. Therefore, the development of a fit-for-purpose animal model for CAD is imperative for future research. Such a development will lead to rapid progress and greater efficiency in CAD research. This paper summarizes the present situation in the field of CAD animal models, and puts forwards ideas for developing a novel animal model of myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.